Relypsa (RLYP) Reports Q4 Loss of $0.80/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Relypsa Announces Fourth Quarter and Full Year 2014 Financial Results
March 11, 2015 4:10 PM EDTREDWOOD CITY, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq: RLYP), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2014.
Cash, cash equivalents and short-term investments totaled $135.8 million at December 31, 2014, compared to $94.8 million at December 31, 2013. Shares outstanding as of December 31, 2014 were 35.0 million. Cash, cash equivalents and short-term investments at December 31, 2014 on a pro forma basis to include the impact of the company's first quarter 2015 activity under its at-the-market offering and an underwritten offering was approximately $349.5 million.
Research and development expenses for the fourth quarter of 2014 were $16.6... More
Relypsa Announces Fourth Quarter and Full Year 2014 Financial Results
March 11, 2015 4:10 PM EDTREDWOOD CITY, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq: RLYP), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2014.
Cash, cash equivalents and short-term investments totaled $135.8 million at December 31, 2014, compared to $94.8 million at December 31, 2013. Shares outstanding as of December 31, 2014 were 35.0 million. Cash, cash equivalents and short-term investments at December 31, 2014 on a pro forma basis to include the impact of the company's first quarter 2015 activity under its at-the-market offering and an underwritten offering was approximately $349.5 million.
Research and development expenses for the fourth quarter of 2014 were $16.6... More
